-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 21, Sunshine Nuowa officially listed on the Sci-tech Innovation Board.
This is the fourth CRO company listed on the Sci-Tech Innovation Board after Medicilon, Chengdu Pioneer, and Haoyuan Pharmaceutical
.
Sunshine Novo plans to publicly issue 20 million RMB common shares this time, and the initial issuance price is 26.
89 yuan per share
.
This is the fourth CRO company listed on the Sci-Tech Innovation Board after Medicilon, Chengdu Pioneer, and Haoyuan Pharmaceutical
.
Sunshine Novo plans to publicly issue 20 million RMB common shares this time, and the initial issuance price is 26.
89 yuan per share
.
According to the prospectus, the operating income of Sunshine Nuowa in the last three years was 135 million yuan, 233 million yuan, and 347 million yuan, with a compound annual growth rate of 60%; the deduction of non-net profits in the last three years was 200,200,700 yuan and 4,642.
34 respectively.
The annual compound growth rate exceeded 50%
.
( Sina Pharmaceutical News )
34 respectively.
The annual compound growth rate exceeded 50%
.
( Sina Pharmaceutical News )
On June 21, Sunshine Nuowa officially listed on the Sci-tech Innovation Board.
This is the fourth CRO company listed on the Sci-Tech Innovation Board after Medicilon, Chengdu Pioneer, and Haoyuan Pharmaceutical
.
Sunshine Novo plans to publicly issue 20 million RMB common shares this time, and the initial issuance price is 26.
89 yuan per share
.
This is the fourth CRO company listed on the Sci-Tech Innovation Board after Medicilon, Chengdu Pioneer, and Haoyuan Pharmaceutical
.
Sunshine Novo plans to publicly issue 20 million RMB common shares this time, and the initial issuance price is 26.
89 yuan per share
.
According to the prospectus, the operating income of Sunshine Nuowa in the last three years was 135 million yuan, 233 million yuan, and 347 million yuan, with a compound annual growth rate of 60%; the deduction of non-net profits in the last three years was 200,200,700 yuan and 4,642.
34 respectively.
The annual compound growth rate exceeded 50%
.
( Sina Pharmaceutical News )
34 respectively.
The annual compound growth rate exceeded 50%
.
( Sina Pharmaceutical News )